Orphan Drug Exclusivity (ODE): The Seven-Year Monopoly The Orphan Drug Act grants seven years of market exclusivity to drugs treating rare diseases, defined as conditions affecting fewer than 200,000 patients in the United States
Importantly, patients should not discontinue GLP-1 therapy without medical guidance, as the benefits for diabetes management or weight loss typically outweigh the temporary inconvenience of hair shedding
Side effects often appear during the early weeks of treatment or after dose increases
General Eye Comfort: It is suitable for anyone seeking relief from temporary or chronic dry eye symptoms
doi: 10.3389/fendo.2022.821113 Received 23 November 2021 Accepted 07 February 2022 Published 20 April 2022 Volume 13 - 2022 Edited by Paolo Moghetti, University of Verona, Italy Reviewed by Antonio Aversa, University of Catanzaro, Italy Updates Copyright 2022 Pelusi
While Novo Nordisk and Lilly are the most prominent players, they are not alone